ライフサイエンスコーパス: gastroesophageal

1 Gastroesophageal acid reflux at each of the pH sensors e

2 specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA).

3 Patients with advanced gastric or gastroesophageal adenocarcinoma need more efficacious an

4 Chemoradiation After Resection of Gastric or Gastroesophageal Adenocarcinoma) assessed whether a post

5 atients with advanced, untreated gastric, or gastroesophageal adenocarcinoma.

6 rognostic factor in patients with resectable gastroesophageal adenocarcinomas with and without neoadj

7 nset in 6 of 16 patients (38%): prostate and gastroesophageal adenocarcinomas, myeloma, melanoma, col

8 ce of the ischemia after gastrointestinal or gastroesophageal anastomosis.

9 Children experiencing gastroesophageal and extraesophageal reflux are often pr

10 Amplification of the MET proto-oncogene in gastroesophageal cancer (GEC) may constitute a molecular

11 Many miRNAs are dysregulated in gastroesophageal cancer cells via alterations in transcr

12 ative chemotherapy plus surgery for operable gastroesophageal cancer from July 1, 1994, through April

13 ) expression may help to stratify breast and gastroesophageal cancer patients for HER2-targeting ther

14 SI, and survival in patients with resectable gastroesophageal cancer randomized to surgery alone or p

15 Gastroesophageal cancer resections are associated with s

16 to reintervene and rescue patients following gastroesophageal cancer resections in England.

17 cer, head and neck squamous cell carcinomas, gastroesophageal cancer, and anal cancer).

18 The incidence of gastroesophageal cancers is increasing each year, but de

19 miRNAs contribute to gastroesophageal carcinogenesis by altering expression o

20 ater understanding of the roles of miRNAs in gastroesophageal carcinogenesis could provide insights i

21 oncoding RNAs that have been associated with gastroesophageal carcinogenesis.

22 correlate with the worst prognosis of human gastroesophageal carcinoma.

23 tiated neoplasms, which are similar to human gastroesophageal carcinoma.

24 s study aimed to determine the prevalence of gastroesophageal disease (GERD) and extraesophageal mani

25 PIs) are used for the long-term treatment of gastroesophageal disorders and the non-prescription medi

26 It is used off-label to treat gastroesophageal, endometrial, cervical, prostate, and h

27 Gastroesophageal function was assessed by clinical valid

28 Gastroesophageal function was evaluated using a clinical

29 sease-specific survival (DSS) for resectable gastroesophageal (GE) junction and gastric adenocarcinom

30 chemotherapy regimen for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma and is as

31 iate esophageal versus gastric epithelium in gastroesophageal junction (GEJ) biopsies, the histology

32 be valid treatment options in patients with gastroesophageal junction (GEJ) cancer.

33 Lewis esophagectomy (TTIL) for esophageal or gastroesophageal junction (GEJ) cancer.

34 ction of stage IB through IV (M0) gastric or gastroesophageal junction adenocarcinoma were randomly a

35 gnosis in patients with distal esophageal or gastroesophageal junction adenocarcinoma who have receiv

36 rpose After curative resection of gastric or gastroesophageal junction adenocarcinoma, Intergroup Tri

37 ion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative

38 nts with resectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

39 radiochemotherapy for high risk gastric and gastroesophageal junction adenocarcinoma: Demonstrated s

40 veness in reducing mortality from esophageal/gastroesophageal junction adenocarcinomas has not been e

41 ed by gastroesophageal reflux disease in the gastroesophageal junction and associated with tumorigene

42 ined as eradication of IM (in esophageal and gastroesophageal junction biopsy specimens), documented

43 reviously untreated metastatic esophageal or gastroesophageal junction cancer were randomly assigned

44 otherapy for locally advanced esophageal and gastroesophageal junction cancers is based on a few posi

45 Implantation of a MSA around the gastroesophageal junction has been shown to be a safe an

46 ith adenocarcinoma of the gastric cardia and gastroesophageal junction have no history of reflux.

47 We studied the gastroesophageal junction in asymptomatic volunteers wit

48 the lower frequency of tumors arising at the gastroesophageal junction in comparison with distal gast

49 carcinomas arising in the stomach or in the gastroesophageal junction in patients with HER2-positive

50 Adenocarcinoma of the gastroesophageal junction is an aggressive disease, with

51 tients with resectable adenocarcinoma of the gastroesophageal junction treated with or without neoadj

52 thoracic esophageal carcinoma, including the gastroesophageal junction tumors (Siewert I), were rando

53 cancer localized in the distal esophagus or gastroesophageal junction undergoing McKeown TMIE or Ivo

54 ble adenocarcinoma of the lower esophagus or gastroesophageal junction were reviewed.

55 Manometric values of "gastroesophageal junction" significantly increased at 12

56 c oesophagogastric (gastric, oesophageal, or gastroesophageal junction) cancer.

57 py of local and locally advanced esophageal, gastroesophageal junction, and gastric adenocarcinomas,

58 lumnar junction and 3) 5-10 mm distal to the gastroesophageal junction, as demarcated by the top of t

59 metastatic adenocarcinoma of the stomach and gastroesophageal junction.

60 correlated with the (18)F-FDG uptake at the gastroesophageal junction.

61 asia seen in some cases, particularly at the gastroesophageal junction.

62 ogy, and recurrence patterns associated with gastroesophageal malignancies suggest the need to split

63 with advanced lung, colorectal, pancreatic, gastroesophageal, or breast cancer between 1998 and 2005

64 doscopic capture from patients with gastric, gastroesophageal, or esophageal cancer who are administe

65 moderate to severe abdominal pain, a severe gastroesophageal reflex, and moderate to severe depressi

66 point), obstructive sleep apnea (+1 point), gastroesophageal reflux (+1 point), and depression (+1 p

67 omorbidities were allergic rhinitis (62.4%), gastroesophageal reflux (42.1%), sinusitis (37.9%), nasa

68 The contribution of gastroesophageal reflux (GER) and vagal function to esop

69 Dental erosion is a complication of gastroesophageal reflux (GER) in adults; in children, it

70 Gastroesophageal reflux (GER) is a disorder that is comm

71 The prevalence of abnormal acid gastroesophageal reflux (GER) is higher in patients with

72 Asymptomatic gastroesophageal reflux (GER) is prevalent in children w

73 f a disease engendered more controversy than gastroesophageal reflux (GER), a highly prevalent condit

74 sts with erosive tooth wear have significant gastroesophageal reflux (GERD), despite minor reflux sym

75 ocephaly, developed intellectual disability, gastroesophageal reflux and a seizure disorder.

76 There were 7 million diagnoses of gastroesophageal reflux and almost 4 million diagnoses o

77 tissue remodeling is associated with chronic gastroesophageal reflux and constitutes a premalignant l

78 BE is associated with chronic gastroesophageal reflux and esophageal cancer.

79 because of both mechanical effects promoting gastroesophageal reflux and nonmechanical effects.

80 also significant improvements in symptoms of gastroesophageal reflux and rhinitis, bronchial reversib

81 index greater than 4 on pH monitoring and/or gastroesophageal reflux and/or herniated wrap on upper g

82 Nissen fundoplication for gastroesophageal reflux can be followed by troublesome s

83 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

84 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

85 The presence of gastroesophageal reflux disease (26%), esophageal strict

86 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

87 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

88 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

89 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

90 and evaluate esophageal disorders, including gastroesophageal reflux disease (GERD) and eosinophilic

91 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

92 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

93 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

94 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

95 Management of gastroesophageal reflux disease (GERD) commonly starts w

96 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

97 surgery, highly variable rates of recurrent gastroesophageal reflux disease (GERD) have been reporte

98 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

99 The prevalence of gastroesophageal reflux disease (GERD) in Africa is not

100 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

101 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

102 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

103 There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United Sta

104 Gastroesophageal reflux disease (GERD) increases EAC ris

105 Gastroesophageal reflux disease (GERD) is a common comor

106 Gastroesophageal reflux disease (GERD) is a common diagn

107 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

108 Gastroesophageal reflux disease (GERD) is associated wit

109 Endoscopic management of gastroesophageal reflux disease (GERD) is being employed

110 Gastroesophageal reflux disease (GERD) is caused by gast

111 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

112 Gastroesophageal reflux disease (GERD) is defined by rec

113 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

114 Gastroesophageal reflux disease (GERD) is prevalent worl

115 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

116 Gastroesophageal reflux disease (GERD) is the most commo

117 Gastroesophageal reflux disease (GERD) is the most preva

118 Gastroesophageal reflux disease (GERD) is the strongest

119 Many individuals with gastroesophageal reflux disease (GERD) never visit their

120 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

121 Refractory gastroesophageal reflux disease (GERD) reduces quality o

122 Gastroesophageal reflux disease (GERD) seems to increase

123 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

124 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

125 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

126 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

127 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

128 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

129 this study was to appraise the prevalence of gastroesophageal reflux disease (GERD), esophagitis, and

130 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

131 Gastroesophageal reflux disease (GERD), functional dyspe

132 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

133 ed the accuracy of frequency and duration of gastroesophageal reflux disease (GERD), using data from

134 Gastroesophageal reflux disease (GERD), which leads to a

135 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

136 can individuals have a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal a

137 defined as a decrease of 50% or more in the Gastroesophageal Reflux Disease (GERD)-Health Related Qu

138 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

139 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

140 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

141 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

142 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

143 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

144 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

145 a novel device for the surgical treatment of gastroesophageal reflux disease (GERD).

146 halasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD).

147 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

148 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

149 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

150 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

151 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

152 Gastroesophageal reflux disease (GORD) is a chronic and

153 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

154 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

155 onitoring on therapy in patients with proven gastroesophageal reflux disease [GERD]), to document phy

156 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

157 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

158 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

159 ulosis is associated with conditions such as gastroesophageal reflux disease and diabetes mellitus, a

160 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

161 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

162 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

163 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

164 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

165 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

166 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

167 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

168 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

169 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

170 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

171 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

172 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

173 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

174 Most patients with gastroesophageal reflux disease experience symptomatic r

175 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

176 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

177 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

178 ed strong genetic correlations of BE/EA with gastroesophageal reflux disease in male individuals and

179 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

180 Gastroesophageal reflux disease is a highly prevalent di

181 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

182 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

183 Diagnosis of GERD was by means of the gastroesophageal reflux disease questionnaire (GERDQ) wh

184 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

185 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

186 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

187 The history of gastroesophageal reflux disease was highly prevalent in

188 Gastroesophageal reflux disease was identified as an imp

189 De novo gastroesophageal reflux disease was reported in 43.8%.

190 screening ages for patients with symptomatic gastroesophageal reflux disease were older (58 for men a

191 as chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease were only associated wit

192 Patients with gastroesophageal reflux disease who have a partial respo

193 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

194 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

195 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

196 ibly due to increased abdominal pressure and gastroesophageal reflux disease, although this pathogeni

197 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

198 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

199 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

200 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

201 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

202 Risk factors include gastroesophageal reflux disease, central obesity, and sm

203 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

204 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

205 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

206 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

207 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

208 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

209 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

210 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

211 Triggered by gastroesophageal reflux disease, the origin of this meta

212 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

213 Except for gastroesophageal reflux disease, which showed a higher r

214 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

215 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

216 ery effective and long-lasting treatment for gastroesophageal reflux disease.

217 Obesity is associated with a risk of gastroesophageal reflux disease.

218 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

219 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

220 st frequently performed surgical therapy for gastroesophageal reflux disease.

221 ved cells is a novel potential treatment for gastroesophageal reflux disease.

222 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

223 gents widely prescribed for the treatment of gastroesophageal reflux disease.

224 to evaluate for the presence of concomitant gastroesophageal reflux disease.

225 thereby conclusively distinguishing it from gastroesophageal reflux disease.

226 fundoplication is an effective treatment for gastroesophageal reflux disease.

227 places esophageal squamous mucosa damaged by gastroesophageal reflux disease.

228 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

229 cough may have abnormal proximal exposure to gastroesophageal reflux documented by HMII that would ha

230 sphincter (UES) to simulated or spontaneous gastroesophageal reflux have shown conflicting results.

231 Subjects reporting nocturnal gastroesophageal reflux in both 1999 and 2010 had more N

232 he diagnosis of cough, LPR, or asthma due to gastroesophageal reflux is difficult, as no criterion st

233 Gastroesophageal reflux is the main risk factor for esop

234 allograft injury from donor-directed Abs or gastroesophageal reflux led to new ColV and KAT Abs post

235 As gastroesophageal reflux persists or recurs in 43% of chi

236 There is significant though mild gastroesophageal reflux postoperatively in 46% of patien

237 rative complications, sleep difficulties and gastroesophageal reflux progressively worsened during fo

238 ireflux surgery, 17.7% experienced recurrent gastroesophageal reflux requiring long-term medication u

239 poorly described, and the risk of worsening gastroesophageal reflux requiring revision may be higher

240 Gastroesophageal reflux scores were higher in overweight

241 t questionnaire was considered diagnostic of gastroesophageal reflux symptoms (GERD).

242 based on the modified Rome III criteria) and gastroesophageal reflux symptoms (GERS) in a population-

243 Apoptosis pathway, gastroesophageal reflux symptoms (reflux), higher body m

244 eep apnea and to determine whether nocturnal gastroesophageal reflux symptoms affect the relationship

245 estioned regarding severity of their typical gastroesophageal reflux symptoms and presence of nocturn

246 nal GERD in 1999 (>/=3 episodes of nocturnal gastroesophageal reflux symptoms per week) had an OR of

247 Barrett's esophagus patients with nocturnal gastroesophageal reflux symptoms should be further evalu

248 's esophagus was associated with more severe gastroesophageal reflux symptoms, and nocturnal reflux s

249 al reflux symptoms and presence of nocturnal gastroesophageal reflux symptoms.

250 ymptom control in up to 50% of patients with gastroesophageal reflux symptoms.

251 The rate of gastroesophageal reflux was comparable with prior studie

252 Gastroesophageal reflux was defined by abnormal pH-testi

253 At 6 months, gastroesophageal reflux was evaluated by 24-hour pH test

254 Gastroesophageal reflux was more common among patients w

255 Gastroesophageal reflux was reported in 50.0% (40 vs 27

256 Objective evidence of gastroesophageal reflux was seen in 46% patients postope

257 Gastroesophageal reflux was the most common GI diagnosis

258 Chronic sinusitis and gastroesophageal reflux were also associated with exacer

259 From 1995 to 2003, 461 patients with gastroesophageal reflux were enrolled in 4 randomized co

260 s have failed to demonstrate that preventing gastroesophageal reflux with antireflux surgery halts th

261 f unproven efficacy and focus on controlling gastroesophageal reflux with reflux-reducing medication

262 Infantile colic, gastroesophageal reflux, and constipation are the most c

263 pse include neck flexion, airway secretions, gastroesophageal reflux, and sleep deprivation.

264 is used variably to prevent complications of gastroesophageal reflux, but its effectiveness is unprov

265 trophy (SMA) notes that patients suffer from gastroesophageal reflux, constipation and delayed gastri

266 discussed: rhinitis, chronic rhinosinusitis, gastroesophageal reflux, obstructive sleep apnoea, vocal

267 in the postoperative period from SSc-related gastroesophageal reflux, renal impairment, and skin fibr

268 , sex, percent predicted FEV1, self-reported gastroesophageal reflux, St. George's Respiratory Questi

269 pump inhibitors (PPIs) are popular drugs for gastroesophageal reflux, which are now available for lon

270 BACKGROUND & AIMS: Central obesity promotes gastroesophageal reflux, which may be related to increas

271 esophagus and may work synergistically with gastroesophageal reflux.

272 criteria and two with findings secondary to gastroesophageal reflux.

273 leaks and strictures, gastric dilation, and gastroesophageal reflux.

274 , abdominal pain, diarrhea, weight loss, and gastroesophageal reflux.

275 Barrett's esophagus segments and persistent gastroesophageal reflux.

276 frequently performed surgical procedure for gastroesophageal reflux.

277 fundoplication for the surgical treatment of gastroesophageal reflux.

278 choanal atresia repair, and/or treatment of gastroesophageal reflux.

279 gher scores indicating better function), and gastroesophageal reflux.

280 n, poor overall health, home oxygen use, and gastroesophageal reflux.

281 Gastroesophageal reflux/dysphagia and asthma/rhinitis re

282 For gastroesophageal resections combined, adjusted mortality

283 nclude younger age at presentation, previous gastroesophageal surgery or ulcers as an etiology, and a

284 Each type of gastroesophageal tumor has a unique gene expression prof

285 pes of cancer, including HER2-overexpressing gastroesophageal tumors.

286 y is common in cirrhotic patients with acute gastroesophageal variceal bleeding and is an independent

287 a lower rate of abdominal and chest varices, gastroesophageal variceal bleeding and refractory ascite

288 cotropin stimulation test in 157 episodes of gastroesophageal variceal bleeding in 143 patients with

289 Gastroesophageal variceal bleeding in patients with cirr

290 We present a case of a patient with massive gastroesophageal variceal bleeding refractory to numerou

291 utcomes of patients with cirrhosis and acute gastroesophageal variceal bleeding remains unknown.

292 mulation test in patients with cirrhosis and gastroesophageal variceal bleeding.

293 ich may induce lethal complications, such as gastroesophageal variceal hemorrhage and hepatic encepha

294 clinical trial to assess the development of gastroesophageal varices (GEV).

295 The accurate prediction of the risk of gastroesophageal varices could spare unnecessary endosco

296 We assessed the course of gastroesophageal varices in a large cohort of patients w

297 eeded to eradicate varices; no bleeding from gastroesophageal varices was observed after eradication.

298 tension (PH) has been exclusively devoted to gastroesophageal varices-related events at different fra

299 ch ultimately causes portal hypertension and gastroesophageal varices.

300 children with biliary atresia and high-risk gastroesophageal varices.